Shares in Celgene fell as much as 8 percent Monday after the company presented data at the ASH annual meeting suggesting that patients taking the company's multiple myeloma drug Revlimid as a maintenance therapy for an extended period of time had a higher incidence of certain types of secondary cancers compared to patients receiving placebo.
Reference Articles
Continuous treatment with Revlimid for patients with multiple myeloma following autologous stem cell transplant evaluated by Intergroupe Francophone du Myelome (IFM) of Phase III study (IFM 2005 02) - (Celgene)
Celgene shares plummet on Revlimid malignancy data - (Forexpros)
Celgene shares drop on concerns about Revlimid data (free preview) - (The Wall Street Journal)
Celgene: Revlimid cancer risk knocks stock - (TheStreet.com)
Celgene shares fall on Revlimid concerns - (Yahoo!Finance)
**published in "First Word"
No comments:
Post a Comment